LCM
APLS

Legato Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Legato Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,825
Closed -$578K – 561
2024
Q1 		$578K Buy
9,825
+5,760
+142% +$367K 0.07% 410
2023
Q4 		$243K Sell
4,065
-2,415
-37% -$123K 0.03% 511
2023
Q3 		$246K Sell
6,480
-2,382
-27% -$105K 0.04% 498
2023
Q2 		$807K Buy
8,862
+1,901
+27% +$164K 0.11% 307
2023
Q1 		$459K Hold
6,961
– – 0.08% 372
2022
Q4 		$360K Buy
+6,961
New +$369K 0.07% 397

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Legato Capital Management's APLS Position: Q2 2024 in Review

Legato Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 9,825 shares — an estimated $578K sold.

Legato Capital Management first reported a position in APLS in Q4 2022 and held it in 6 quarters. The position peaked at $807K in Q2 2023. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Legato Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Legato Capital Management sold 9,825 Apellis Pharmaceuticals shares in Q2 2024, an estimated $578K.
  • Legato Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Legato Capital Management's Apellis Pharmaceuticals position peaked at $807K in Q2 2023.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Legato Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.